An innovative approach to polycystic ovary syndrome

Abstract

Myo-inositol and D-chiro-inositol are insulin sensitising agents. In the ovary, myo-inositol acts as second messenger of Follicle Stimulating Hormone (FSH). Both molecules were administered to Polycystic Ovary Syndrome (PCOS) women. The gynaecologist Vittorio Unfer was the first to give specific value to myo-inositol for the treatment of PCOS: this important innovation opened new ways of research to identify efficient therapies based on myo-inositol alone or with low doses of D-chiro-inositol. Significant successes were also gained using myo-inositol in treating male and female infertility. Unfer’s researches allowed to identify “the D-Chiro-Inositol Paradox in the Ovary” and the best myo-inositol/D-chiro-inositol ratio (40:1) for the treatment of PCOS. Furthermore, his studies allowed to improve the inositol’s efficacy using alpha-lactalbumin. As shown in this review, the main stages of Unfer’s scientific career have been closely intertwined with important phases of the recent pharmacological research about the topic.

Keywords:

• Alpha-lactalbumin
• fertilisation
• inositol
• insulin
• insulin resistance
• ovary
• PCOS
• Unfer
• vitamin D

Disclosure statement

Patrizia Logoteta is employee at Lo.Li.Pharma Company. The other authors declare no competing interests.

Author contribution

All authors contributed equally to the writing of the manuscript.